PAFAH1B2

Across TCGA pan-cancer cohorts, PAFAH1B2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PAFAH1B2 data layer compared with 22 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher PAFAH1B2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated PAFAH1B2 expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

LUAD, HNSC, and PDAC are the cancer types where PAFAH1B2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Tertile	II,III,IV	0.332	0.823	.001	42	view →
HNSC	DFS	Tertile	III,IV	0.946	0.666	.001	23	view →
PDAC	DFS	Quartile	III,IV	0.177	0.904	.005	17	view →
COAD	DFS	Median	IV	0.493	0.944	.031	6	view →
LSCC	OS	Median	All	0.739	0.885	.018	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PAFAH1B2–LUAD (OS)

Open the LUAD breakdown →